An Analysis of Patients' Reviews for Drugs Side Effects in Parkinson's Disease: A Machine Learning Method
Abstract
A timely and accurate diagnosis of Parkinson's Disease (PD) is very important for its effective management and treatment. Medications play a crucial role in managing PD symptoms and improving patients' quality of life. In this work, four drugs for the treatment of PD are reviewed for their use and side effects. While clinical trials and medical literature provide valuable information about the efficacy and safety profiles of drugs, they often have limitations such as small sample sizes, short duration of observation which may not fully capture the diverse experiences and potential side effects encountered by patients. Thus, we provide a complementary study on these drugs from patients’ reviews in drugs.com using text mining approach. The analysis of patients’ reviews is important as it provides real-world insights into the experiences of individuals who have actually used these medications for PD. The outcome of this work may help healthcare providers make more informed decisions about treatment options and provide better support and guidance to patients with PD.
Keywords
Full Text:
AbstractReferences
Velázquez-Paniagua, M., et al., Current treatments in Parkinson's including the proposal of an innovative dopamine microimplant. Revista Médica del Hospital General de México, 2016. 79(2): p. 79-87.
Ghane, M., et al., Enhanced decision tree induction using evolutionary techniques for Parkinson's disease classification. Biocybernetics and Biomedical Engineering, 2022. 42(3): p. 902-920.
Saint-Hilaire, M.-H. and C.-A. Thomas. Delivering a Diagnosis of Parkinson's Disease and Parkinsonism with Wisdom and Sensitivity. in Seminars in Neurology. 2023. Thieme Medical Publishers, Inc.
Goldenberg, M.M., Medical management of Parkinson’s disease. Pharmacy and Therapeutics, 2008. 33(10): p. 590.
Halkias, I.A.C., et al., When Should Levodopa Therapy be Initiated in Patients with Parkinson’s Disease? Drugs & Aging, 2007. 24(4): p. 261-273.
Nilashi, M. and R.A. Abumalloh, Parkinson's Disease Facts and Figures. Journal of Soft Computing and Decision Support Systems, 2023. 10(5): p. 1-6.
Nilashi, M., O. Ibrahim, and A. Ahani, Accuracy improvement for predicting Parkinson’s disease progression. Scientific reports, 2016. 6(1): p. 34181.
Rezayi, S., et al., Vulnerability of Parkinson’s Patients to COVID?19 and Its Consequences and Effects on Them: A Systematic Review. Parkinson’s Disease, 2023. 2023(1): p. 6272982.
Neirynck, J. and L. Garey, The Prevention of Parkinson Disease. Your Brain and Your Self: What You Need to Know, 2009: p. 49-58.
Al-kuraishy, H.M., et al., New insight on the possible role of statins in Vascular Parkinsonism: A need for presumptive therapy. Ageing Research Reviews, 2024. 95: p. 102209.
Aryal, S., et al., The pathology of Parkinson’s disease and potential benefit of dietary polyphenols. Molecules, 2020. 25(19): p. 4382.
Rabhi, C., et al., Antiangiogenic-like properties of fermented extracts of ayurvedic medicinal plants. Journal of medicinal food, 2015. 18(9): p. 1065-1072.
Hayes, M.T., Parkinson's disease and parkinsonism. The American journal of medicine, 2019. 132(7): p. 802-807.
He, T., et al., Dose–response relationship of levodopa with dyskinesia in Parkinson's disease: A systematic review and meta-analysis. Heliyon, 2024.
Rinaldi, D., et al., The impact of dysphagia in Parkinson's disease patients treated with levodopa/carbidopa intestinal gel. Parkinsonism & Related Disorders, 2023. 109: p. 105368.
Grün, D., et al., Impact of oral COMT-inhibitors on gut microbiota and short chain fatty acids in Parkinson's disease. Parkinsonism & related disorders, 2020. 70: p. 20-22.
Ajala, A., et al., In-silico Screening and ADMET evaluation of Therapeutic MAO-B Inhibitors against Parkinson Disease. Intelligent Pharmacy, 2023.
Espindola, M., et al., Suicide attempt in a dopamine agonist withdrawal syndrome in Parkinson's disease. Parkinsonism & Related Disorders, 2024: p. 106017.
Rascol, O., M. Fabbri, and W. Poewe, Amantadine in the treatment of Parkinson's disease and other movement disorders. The Lancet Neurology, 2021. 20(12): p. 1048-1056.
Isaacson, S.H., et al., Dopamine agonists in Parkinson’s disease: Impact of D1-like or D2-like dopamine receptor subtype selectivity and avenues for future treatment. Clinical Parkinsonism & Related Disorders, 2023: p. 100212.
Shokeen, A., et al., Advancement in herbal drugs for the treatment of Parkinson’s disease, in Targeting Angiogenesis, Inflammation, and Oxidative Stress in Chronic Diseases. 2024, Elsevier. p. 251-276.
Khodadadi, T., et al. Exploring the benefits and drawbacks of machine learning in cybersecurity to strengthen cybersecurity defences. in 2023 IEEE 30th Annual Software Technology Conference (STC). 2023. IEEE.
Zamani, M., et al. Artificial intelligence for promoting equity, diversity, and inclusion. in 2025 International Conference on Artificial Intelligence, Computer, Data Sciences and Applications (ACDSA). 2025. IEEE.
Atefi, K., H. Hashim, and T. Khodadadi. A hybrid anomaly classification with deep learning (DL) and binary algorithms (BA) as optimizer in the intrusion detection system (IDS). in 2020 16th IEEE international colloquium on signal processing & its applications (CSPA). 2020. IEEE.
Chinta, S.V., et al., AI-driven healthcare: Fairness in AI healthcare: A survey. PLOS digital health, 2025. 4(5): p. e0000864-e0000864.
Saeidnia, H.R. and M. Nilashi, From MYCIN to MedGemma: a historical and comparative analysis of healthcare AI evolution. InfoScience Trends, 2025. 2(6): p. 18-28.
Abumalloh, R.A., et al., Blockchain innovations for addressing pharmaceutical counterfeit in the global supply chain: a PLS–ANN approach. International Journal of Production Research, 2026. 64(7): p. 2636-2660.
Alghamdi, A., et al., Accuracy improvements for electroencephalography (EEG) eye state classification using eXtreme gradient boosting and cluster ensembles. Journal on Advances in Signal Processing, 2026. 2026(1): p. 20.
Nilashi, M., et al., Accuracy Analysis of Type-2 Fuzzy System in Predicting Parkinson’s Disease Using Biomedical Voice Measures: M. Nilashi et al. International Journal of Fuzzy Systems, 2024. 26(4): p. 1261-1284.
Nilashi, M., et al., Parkinson’s disease diagnosis using Laplacian score, Gaussian process regression and self-organizing maps. Brain sciences, 2023. 13(4): p. 543.
Zogaan, W.A., et al., A combined method of optimized learning vector quantization and neuro-fuzzy techniques for predicting unified Parkinson's disease rating scale using vocal features. MethodsX, 2024. 12: p. 102553.
Jaiswal, B.P. How support groups help people with Parkinson's. 2022 [cited 2024 21 March]; Available from: https://www.theweek.in/health/more/2022/05/27/how-support-groups-help-people-with-parkinsons.html.
Adam, H., et al., An update on pathogenesis and clinical scenario for Parkinson’s disease: diagnosis and treatment. 3 Biotech, 2023. 13(5): p. 142.
Nilashi, M., et al., An analytical method for measuring the Parkinson’s disease progression: A case on a Parkinson’s telemonitoring dataset. Measurement, 2019. 136: p. 545-557.
Nilashi, M., et al., A hybrid intelligent system for the prediction of Parkinson's Disease progression using machine learning techniques. Biocybernetics and Biomedical Engineering, 2018. 38(1): p. 1-15.
Kispotta, S., D. Das, and S.K. Prusty, A recent update on drugs and alternative approaches for parkinsonism. Neuropeptides, 2024: p. 102415.
Wang, H.-t., et al., Rotigotine transdermal patch for the treatment of neuropsychiatric symptoms in Parkinson's disease: A meta-analysis of randomized placebo-controlled trials. Journal of the Neurological Sciences, 2018. 393: p. 31-38.
Sohya, K., K. O'Hashi, and H. Kunugi, Linking rotigotine, Parkinson's disease, and brain-derived neurotrophic factor, in Genetics, Neurology, Behavior, and Diet in Parkinson's Disease. 2020, Elsevier. p. 221-232.
Lyons, K.E. and R. Pahwa, Outcomes of rotigotine clinical trials: effects on motor and nonmotor symptoms of Parkinson's disease. Neurologic clinics, 2013. 31(3): p. S51-S59.
Wang, A., et al., Preparation and evaluation of rotigotine-loaded implant for the treatment of Parkinson’s disease and its evolution study. Saudi Pharmaceutical Journal, 2016. 24(3): p. 363-370.
Rascol, O., et al., A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. New England Journal of Medicine, 2000. 342(20): p. 1484-1491.
Ahlskog, J.E. and M.D. Muenter, Frequency of levodopa?related dyskinesias and motor fluctuations as estimated from the cumulative literature. Movement disorders: official journal of the Movement Disorder Society, 2001. 16(3): p. 448-458.
Holloway, R.G., et al., Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Archives of neurology, 2004. 61(7): p. 1044-1053.
Pfeiffer, R.F., Potential of transdermal drug delivery in Parkinson’s disease. Drugs & aging, 2002. 19: p. 561-570.
Giladi, N., et al., Rotigotine transdermal patch in early Parkinson's disease: a randomized, double?blind, controlled study versus placebo and ropinirole. Movement disorders, 2007. 22(16): p. 2398-2404.
Group, P.S., A controlled trial of rotigotine monotherapy in early Parkinson's disease. Archives of neurology, 2003. 60(12): p. 1721-1728.
Poewe, W.H., et al., Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. The Lancet Neurology, 2007. 6(6): p. 513-520.
Mizuno, Y., et al., Transdermal rotigotine in early stage Parkinson's disease: A randomized, double?blind, placebo?controlled trial. Movement disorders, 2013. 28(10): p. 1447-1450.
Giladi, N., et al., Rotigotine transdermal patch in early Parkinson's disease: A randomized, double-blind, controlled study versus placebo and ropinirole. Movement Disorders, 2007. 22(16): p. 2398-2404.
Nomoto, M., et al., Transdermal rotigotine in advanced Parkinson’s disease: a randomized, double-blind, placebo-controlled trial. Journal of Neurology, 2014. 261(10): p. 1887-1893.
Sujith, O. and C. Lane, Therapeutic options for continuous dopaminergic stimulation in Parkinson's disease. Therapeutic advances in neurological disorders, 2009. 2(2): p. 105-113.
Hauser, R.A., et al., Duration of benefit per Dose: Carbidopa-Levodopa immediate release vs. extended release capsules (Rytary®). Parkinsonism & Related Disorders, 2021. 82: p. 133-137.
Dhall, R. and D.L. Kreitzman, Advances in levodopa therapy for Parkinson disease: review of RYTARY (carbidopa and levodopa) clinical efficacy and safety. Neurology, 2016. 86(14_supplement_1): p. S13-S24.
basicmedicalkey.com. Drugs for Neurodegenerative Diseases. 2016 [cited 2024 23 March]; Available from: https://basicmedicalkey.com/drugs-for-neurodegenerative-diseases-2/.
Steel, M.J., et al., A case of carbidopa/levodopa associated colitis mimicking inflammatory bowel disease. Human Pathology Reports, 2022. 28: p. 300648.
Zanelli, M., et al., Severe acute colitis related to levodopa treatment. Pathologica-Journal of the Italian Society of Anatomic Pathology and Diagnostic Cytopathology, 2018. 110(1): p. 75-77.
Pahwa, R., et al., Long-term results of carbidopa/levodopa enteral suspension across the day in advanced Parkinson’s disease: Post-hoc analyses from a large 54-week trial. Clinical Parkinsonism & Related Disorders, 2023. 8: p. 100181.
Antonini, A. and P. Odin, Pros and cons of apomorphine and L-dopa continuous infusion in advanced Parkinson's disease. Parkinsonism & related disorders, 2009. 15: p. S97-S100.
Antonini, A., et al., Oral and infusion levodopa-based strategies for managing motor complications in patients with Parkinson’s disease. CNS drugs, 2010. 24: p. 119-129.
Allain, P., et al., Sulfate and cysteine levels in the plasma of patients with Parkinson's disease. Neurotoxicology, 1995. 16(3): p. 527-529.
Ahlskog, J.E., Levodopa, homocysteine and Parkinson's disease: What's the problem? Parkinsonism & Related Disorders, 2023. 109: p. 105357.
Block, G., et al., Comparison of Immediate-Release and Controlled Release Carbidopa/Levodopa in Parkinson’s Disease: A Multicenter 5-Year Study. European Neurology, 2008. 37(1): p. 23-27.
Thakkar, S., et al., 24-Hour Levodopa-Carbidopa Intestinal Gel: Clinical Experience and Practical Recommendations. CNS Drugs, 2021. 35(2): p. 137-149.
Reichmann, H., et al., Pramipexole in routine clinical practice: a prospective observational trial in Parkinson’s disease. CNS drugs, 2003. 17: p. 965-973.
Gu, M., et al., Pramipexole protects against apoptotic cell death by non?dopaminergic mechanisms. Journal of neurochemistry, 2004. 91(5): p. 1075-1081.
Barone, P., et al., Pramipexole versus sertraline in the treatment of depression in Parkinson’s disease: A national multicenter parallel–group randomized study. Journal of neurology, 2006. 253: p. 601-607.
Lieberknecht, V., et al., Antidepressant-like effect of pramipexole in an inflammatory model of depression. Behavioural brain research, 2017. 320: p. 365-373.
Stani?ová, J., P. Miškovský, and V. Šutiak, Amantadine: an antiviral and antiparkinsonian agent. Vet. Med. Czech, 2001. 46(9): p. 244-256.
Krupp, L.B., Fatigue in multiple sclerosis: definition, pathophysiology and treatment. CNS drugs, 2003. 17: p. 225-234.
Li, T.C., M.C. Chan, and N. Lee, Clinical implications of antiviral resistance in influenza. Viruses, 2015. 7(9): p. 4929-4944.
Schwab, R.S., et al., Amantadine in the treatment of Parkinson's disease. Jama, 1969. 208(7): p. 1168-1170.
Crosby, N.J., et al., Amantadine in Parkinson's disease. Cochrane Database of Systematic Reviews, 1996. 2010(1).
Fox, S.H., et al., The Movement Disorder Society evidence?based medicine review update: treatments for the motor symptoms of Parkinson's disease. Movement Disorders, 2011. 26(S3): p. S2-S41.
Crosby, N.J., et al., Amantadine for dyskinesia in Parkinson's disease. Cochrane Database of Systematic Reviews, 1996. 2010(1).
Sawada, H., et al., Amantadine for dyskinesias in Parkinson's disease: a randomized controlled trial. PloS one, 2010. 5(12): p. e15298.
Kondo, T., Drug intervention for freezing of gait resistant to dopaminergic therapy: a pilot study. Parkinsonism & Related Disorders, 2006. 12: p. S63-S66.
Macht, M., et al., Predictors of freezing in Parkinson's disease: a survey of 6,620 patients. Movement disorders, 2007. 22(7): p. 953-956.
Damiano, A., et al., Evaluation of a measurement strategy for Parkinson's disease: assessing patient health-related quality of life. Quality of Life Research, 2000. 9: p. 87-100.
Miyasaki, J., et al., Practice parameter: initiation of treatment for Parkinson’s disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology, 2002. 58(1): p. 11-17.
Quinn, N., Fortnightly Review: Drug treatment of Parkinson's disease. Bmj, 1995. 310(6979): p. 575-579.
Walia, V., C. Garg, and M. Garg, Amantadine exerts anxiolytic like effect in mice: Evidences for the involvement of nitrergic and GABAergic signaling pathways. Behavioural Brain Research, 2020. 380: p. 112432.
Wang, T., et al., Amantadine improves cognitive outcome and increases neuronal survival after fluid percussion traumatic brain injury in rats. Journal of neurotrauma, 2014. 31(4): p. 370-377.
Autry, A.E., et al., NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature, 2011. 475(7354): p. 91-95.
Koller, W.C. and M.G. Rueda, Mechanism of action of dopaminergic agents in Parkinson's disease. Neurology, 1998. 50(6_suppl_6): p. S11-S14.
Riederer, P., et al., Relating mode of action to clinical practice: dopaminergic agents in Parkinson's disease. Parkinsonism & related disorders, 2007. 13(8): p. 466-479.
Hälbig, T.D. and W.C. Koller, Levodopa, in Handbook of Clinical Neurology, W.C. Koller and E. Melamed, Editors. 2007, Elsevier. p. 31-72.
Refbacks
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.